Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Gains from Sales and Divestitures (2019 - 2025)

Cyclerion Therapeutics has reported Gains from Sales and Divestitures over the past 7 years, most recently at $45072.0 for Q3 2025.

  • Quarterly results put Gains from Sales and Divestitures at $45072.0 for Q3 2025, down 20.56% from a year ago — trailing twelve months through Sep 2025 was $45072.0 (down 20.56% YoY), and the annual figure for FY2024 was $71763.0, up 146.92%.
  • Gains from Sales and Divestitures for Q3 2025 was $45072.0 at Cyclerion Therapeutics, up from $30048.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for CYCN hit a ceiling of $143774.0 in Q4 2021 and a floor of $3375.0 in Q2 2023.
  • Median Gains from Sales and Divestitures over the past 5 years was $41715.0 (2024), compared with a mean of $48525.0.
  • Biggest five-year swings in Gains from Sales and Divestitures: tumbled 91.49% in 2023 and later surged 1136.0% in 2024.
  • Cyclerion Therapeutics' Gains from Sales and Divestitures stood at $143774.0 in 2021, then crashed by 62.44% to $53999.0 in 2022, then plummeted by 46.18% to $29063.0 in 2023, then surged by 146.92% to $71763.0 in 2024, then plummeted by 37.19% to $45072.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $45072.0 (Q3 2025), $30048.0 (Q2 2025), and $15024.0 (Q1 2025) per Business Quant data.